FDA-cleared profile

uCT ATLAS Astound with uWS-CT-Dual Energy Analysis; uCT ATLAS with uWS-CT-Dual Energy Analysis

Shanghai United Imaging Healthcare Co.,Ltd. · CT/CTA · FDA-cleared (510(k))

uCT ATLAS Astound and uCT ATLAS are whole-body CT systems for head, body, cardiac, and vascular imaging, with dual-energy analysis options and protocol-governed low-dose lung-screening use within approved programs.

Clinical role
CT acquisition, reconstruction, visualization, and release-specific examination planning.
Images and patients
CT/CTA · Multi-region
Key limitation
Use only cleared populations, protocols, reconstructions, and applications; local dose, image-quality, geometry, and downstream-compatibility acceptance remains required.

Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • Imaging and anatomyCT/CTA · Multi-region
  • Workflow roleCT acquisition, reconstruction, visualization, and release-specific examination planning.
  • Required inputX-ray projection data acquired under supported patient, protocol, contrast, and dose conditions.
  • Output and human actionCross-sectional CT images, reformats, measurements, attenuation maps, and planning datasets for professional review.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
uCT ATLAS Astound and uCT ATLAS are whole-body CT systems for head, body, cardiac, and vascular imaging, with dual-energy analysis options and protocol-governed low-dose lung-screening use within approved programs.
  • Exact FDA submission
  • Checked 2026-09-03
Workflow role
CT acquisition, reconstruction, visualization, and release-specific examination planning.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
X-ray projection data acquired under supported patient, protocol, contrast, and dose conditions.
  • Exact FDA submission
  • Checked 2026-09-03
Output and clinician action
Cross-sectional CT images, reformats, measurements, attenuation maps, and planning datasets for professional review.
  • Exact FDA submission
  • Checked 2026-09-03
Care setting
Hospital and outpatient CT, interventional, oncology, or radiotherapy departments within the cleared scope.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
Qualified CT technologists and trained interpreting or treating physicians.
  • Exact FDA submission
  • Checked 2026-09-03
Limitations
Use only cleared populations, protocols, reconstructions, and applications; local dose, image-quality, geometry, and downstream-compatibility acceptance remains required.
  • Exact FDA submission
  • Checked 2026-09-03
Evidence summary
The exact FDA document reports non-clinical testing, including bench tests and a reader study, for the uCT ATLAS Astound and uCT ATLAS. Bench tests showed CardioBoost and AIIR passed the basic general IQ test per IEC 61223-3-5. Readers rated AIIR and FBP images on a five-point scale; AIIR images were sufficient for diagnosis with quality equal or better than FBP, and CardioBoost images were sufficient for diagnosis with quality equal or better than KARL 3D. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Non-clinical testing including bench test and reader study were conducted for the uCT ATLAS Astound with uWS-CT Dual Energy Analysis and uCT ATLAS with uWS-CT Dual Energy Analysis" … "CardioBoost passed the basic general IQ test which satisfied the requirement of IEC 61223-3-5.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports non-clinical testing, including bench tests and a reader study, for the uCT ATLAS Astound and uCT ATLAS. Bench tests showed CardioBoost and AIIR passed the basic general IQ test per IEC 61223-3-5. Readers rated AIIR and FBP images on a five-point scale; AIIR images were sufficient for diagnosis with quality equal or better than FBP, and CardioBoost images were sufficient for diagnosis with quality equal or better than KARL 3D. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Non-clinical testing including bench test and reader study were conducted for the uCT ATLAS Astound with uWS-CT Dual Energy Analysis and uCT ATLAS with uWS-CT Dual Energy Analysis" … "CardioBoost passed the basic general IQ test which satisfied the requirement of IEC 61223-3-5.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K243617 FDA performance package for uCT ATLAS Astound with uWS-CT-Dual Energy Analysis; uCT ATLAS with uWS-CT-Dual Energy Analysis

  • DesignManufacturer CT-system, reconstruction, dual-energy, dose, image-quality, and software verification and validation
  • PopulationAdult and pediatric whole-body, head, cardiac, vascular, dual-energy, and labeled lung-screening workflows
  • Scopeexact submission
  • Tested versionuCT ATLAS Astound/uCT ATLAS with uWS-CT Dual Energy Analysis
  • IndependenceSponsor or vendor study

K243617

Manufacturer evidence submitted for FDA clearance or approval; local clinical, technical, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
1 exact-submission FDA recall record in the 2026-09-02 openFDA snapshot identify K243617. Affected model, version, unit, correction, and current manufacturer instructions still require local confirmation. FDA recall Z-0221-2026 is Open, Classified for Shanghai United Imaging Healthcare Co., Ltd. Computed Tomography X-ray System, Model:uCT ATLAS MD, Rx Only. FDA reason: Third-party outer covers can become trapped between patient table and gantry, causing mechanical interference during table movement. FDA action: On September 12, 2025, UIH Technologies LLC, issued a recall notification to affected consignees. UIH asked consignees to take the following actions: 1. Ensure patient positioning clearance: When positioning the patient, confirm that arms and legs and clear of all table gaps and moving parts. 2. Avoid use of third-party slickers: We advise against the use of any non-UIH-approved slickers. 3. Service Contact: For technical assistance, contact your United Imaging Service engineer or reach out to our 24/7 Customer Contact Center, Toll-Free: (855) 221-1552/Direct: (832) 699-2799 4.Report adverse events: if any adverse events or quality issue occur, please report them to the FDA via the MedWatch program. 5. Please share this information with all relevant personnel at your facility, including technologist, service staff, and clinical teams.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04

Each published event was manually matched to the exact FDA submission and affected product or version; a recall does not establish an AI-algorithm defect or current site exposure unless the event states that scope.

recall: Z-0221-2026

Open, Classified

2025-10-21

Exact native submission match in the checked openFDA snapshot. Published as a product, system, labeling, or postmarket issue; do not infer an AI-algorithm defect unless the FDA record says so. Confirm affected model, version, units, corrective action, and completion status locally.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: X-ray projection data acquired under supported patient, protocol, contrast, and dose conditions.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-03 · K243617 FDA decision source

  2. Routing

    Source context, not route validation: Scanner-console and DICOM workflow to PACS, advanced visualization, and treatment-planning systems; validate worklist, protocol, dose record, geometry, series labels, and routing.

    Scope: Product family. Current vendor materials are product-family evidence for K243617; confirm the exact cleared version, enabled options, deployment, and local compatibility.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · K243617 FDA decision source · United Imaging uCT ATLAS

  3. AI processing

    Source context, not route validation: Installed CT scanner hardware, console software, reconstruction options, and supported accessories.

    Scope: Product family. Current vendor materials are product-family evidence for K243617; confirm the exact cleared version, enabled options, deployment, and local compatibility.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · K243617 FDA decision source · United Imaging uCT ATLAS

  4. Returned objects

    Source context, not route validation: Cross-sectional CT images, reformats, measurements, attenuation maps, and planning datasets for professional review.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-03 · K243617 FDA decision source

  5. Viewer/worklist/report

    Unresolved route: Cross-sectional CT images, reformats, measurements, attenuation maps, and planning datasets for professional review.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-03 · K243617 FDA decision source

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Installed CT scanner hardware, console software, reconstruction options, and supported accessories.
  • Product family
  • Checked 2026-09-03

Current vendor materials are product-family evidence for K243617; confirm the exact cleared version, enabled options, deployment, and local compatibility.

Integration
Scanner-console and DICOM workflow to PACS, advanced visualization, and treatment-planning systems; validate worklist, protocol, dose record, geometry, series labels, and routing.
  • Product family
  • Checked 2026-09-03

Current vendor materials are product-family evidence for K243617; confirm the exact cleared version, enabled options, deployment, and local compatibility.

Security
United Imaging Healthcare's cybersecurity page lists a secure development lifecycle and controls: firewall, encrypted connections, OS hardening, antivirus, patches, authentication, audit log, disk and transmission encryption. Company-level, not release-specific.
  • Vendor-wide
  • Checked 2026-10-25

Vendor statement, not an attestation; exact-release scope is not established.

Training
Only qualified ct technologists and trained interpreting or treating physicians should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Use only cleared populations, protocols, reconstructions, and applications; local dose, image-quality, geometry, and downstream-compatibility acceptance remains required.
  • Product family
  • Checked 2026-09-03

Current vendor materials are product-family evidence for K243617; confirm the exact cleared version, enabled options, deployment, and local compatibility.

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, outputs, and enabled AI functions to K243617 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Scanner-console and DICOM workflow to PACS, advanced visualization, and treatment-planning systems; validate worklist, protocol, dose record, geometry, series labels, and routing.

product family · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally. Vendor statements are current product-family context; confirm the exact cleared release and installed options.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Use only cleared populations, protocols, reconstructions, and applications; local dose, image-quality, geometry, and downstream-compatibility acceptance remains required.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

No exact-product price was found in the reviewed public material; vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Use only cleared populations, protocols, reconstructions, and applications; local dose, image-quality, geometry, and downstream-compatibility acceptance remains required.

product family · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. Vendor statements are current product-family context; confirm the exact cleared release and installed options.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243617
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-05-16
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
25Fields reviewed
12Source classes checked
0Awaiting review PubMed leads
0Awaiting review trial leads
0Unreviewed FDA recall leads

Recovered from the prior exact-submission extraction and normalized under the current provenance rules. Exact FDA decision materials were reviewed for identity, indication, users, workflow, limitations, and submitted performance. Current vendor material is labeled product-family context where it does not establish the exact release. PubMed and ClinicalTrials.gov results are retained as candidate evidence with version applicability pending; CMS reimbursement context and exact-identifier openFDA postmarket results were also checked. Pricing, final security architecture, contracted services, enabled options, and local interoperability remain organization-specific evidence. Automated exact-name discovery found 0 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. 1 FDA recall candidate was manually reviewed: 1 published and 0 rejected as a neighboring or otherwise inapplicable version. Native FDA recall identifiers produced 1 postmarket candidate record; 1 has been reviewed (1 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, vendor documentation, fda decision material, vendor product page, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

9 sources - 2 history items

Source ledger

  1. K243617 FDA decision source

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, purpose, modality, anatomy

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. FDA recall Z-0221-2026: Shanghai United Imaging Healthcare Co., Ltd. Computed Tomography X-ray System, Model:uCT ATLAS MD, Rx Only

    U.S. Food and Drug Administration - Published 2025-10-21 - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  7. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  8. United Imaging uCT ATLAS

    United Imaging - Accessed 2026-09-03

    Scope: productFamilyContext, workflowRole, implementationCapabilities

  9. United Imaging Healthcare Cybersecurity

    United Imaging Healthcare - Accessed 2026-10-25

    Scope: security

Research history

  1. K243617 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

Alternatives

Related tools to compare

FDA-cleared K241079

uCT 780

Shanghai United Imaging Healthcare Co., Ltd.

Authorized purpose: uCT 780 produces whole-body cross-sectional CT images, including head, neck, cardiac, and vascular imaging, supports protocol-governed low-dose lung cancer screening and dual-energy material visualization, and uses DELTA deep-learning reconstruction for adult head, chest, abdomen, cardiac, and vascular applications.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2025-01-07
FDA-cleared K220961

Deep Learning Image Reconstruction

GE Healthcare Japan Corporation

TrueFidelity deep-learning CT reconstruction produces selectable-strength images for supported head, whole-body, cardiac, and vascular applications on the Discovery CT750 HD family.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2022-07-29
FDA-cleared K212441

Philips Incisive CT

Philips Healthcare (Suzhou) Co., Ltd.

Philips Incisive CT provides head, whole-body, cardiac, and vascular CT imaging for patients of all ages and can support qualified low-dose lung screening under labeled programs and protocols.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2022-04-27
FDA-cleared K213999

Deep Learning Image Reconstruction

GE Medical Systems, LLC.

TrueFidelity deep-learning CT reconstruction supports head, whole-body, cardiac, and vascular imaging on specified Revolution CT configurations with release-specific speed and image-quality updates.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2022-02-18

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history